Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.